Xintela reports safety results from the XSTEM clinical study in difficult-to-heal venous leg ulcers

Xintela announces that the XSTEM® treatment in the clinical Phase I/IIa study on patients with difficult-to-heal venous leg ulcers was considered safe and well tolerated and thus achieved the primary objective of the study. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela’s completed Phase I/IIa […]

Xintela AB changes Certified Adviser to Västra Hamnen Corporate Finance AB

Xintela AB announces today that the company is changing its Certified Adviser to Västra Hamnen Corporate Finance AB. Xintela AB has entered into an agreement with Västra Hamnen Corporate Finance AB regarding the role as Certified Adviser. Västra Hamnen Corporate Finance AB will assume the role of Certified Adviser on June 1, 2026. Until then, […]

Xintela granted US patent for XSTEM treatment of difficult-to-heal wounds and skin defects

Xintela (XINT) announces today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of the company’s stem cell product XSTEM® for the treatment and regeneration of skin defects, including difficult-to-heal (chronic) wounds. The patent, US 12,599,633, issues today and protects XSTEM in the United States until 7 June […]